Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial
Primary resultResult — go to the resultHazard ratio 1.06 95% CI 0.86–1.30Authors' conclusion
In adults with coronary artery disease, rosuvastatin and atorvastatin showed comparable efficacy for the composite outcome of all cause death, myocardial infarction, stroke, or any coronary revascularisation at three years. Rosuvastatin was associated with lower LDL cholesterol levels but a higher risk of new onset diabetes mellitus requiring antidiabetics and cataract surgery compared with atorvastatin.
Study context
- Population
- Adults (age ≥19 years) with CAD, South Korea, September 2016 to November 20194,341 (98.7%) completed
- Participants
- 4,400 adults
- Comparison
- Rosuvastatin vs atorvastatin
- Rosuvastatinn = 2,204
- Atorvastatinn = 2,196reference
- Primary endpoint
- Composite of:
- All-cause death
- MI
- Stroke
- Any coronary revascularisation
- Follow-up
- 3 years
Methodological detailsopen label, multicentre, 2×2 factorial randomisation, 12 hospitals in South Korea
- Open label
- Multicentre
- 2×2 factorial randomisation
- 12 hospitals in South Korea
Primary result
As reported in the abstract
Hazard ratio
1.06
95% CI 0.86–1.30
P = 0.58
Events by treatment group
Rosuvastatinvs Atorvastatin
HR 1.06 (95% CI 0.86–1.30); P = 0.58
Secondary outcomes
Mean LDL-C during treatment
Mean daily dose of study drugs · 3 years
- Mean LDL-C during treatment: P<0.001
- Mean daily dose of study drugs: P<0.001
Safety
| Outcome | Rosuvastatin | Atorvastatin | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| New-onset DM requiring initiation of antidiabetics | 7.2% | 5.3% | 1.39 (1.03–1.87) | P = 0.03 | |
| Cataract surgery | 2.5% | 1.5% | 1.66 (1.07–2.58) | P = 0.02 | |
| 0.20.5125Hazard ratio (log scale) |
Other safety endpoints
- Did not differ between the two groups
Original publication
Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial. BMJ. Published 18 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →